A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of PRA023 in participants with
moderately to severely active Crohn's Disease.
After the completion of the 12-week induction period, all participants have the option to
continue in the open-label extension for another 38 weeks.